Hereditary Angioedema Market Report 2026

The hereditary angioedema market size has grown strongly in recent years. It will grow from $2.81 billion in 2025 to $3.04 billion in 2026 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to increasing clinical awareness of rare genetic disorders, availability of plasma-derived c1 esterase inhibitors, expansion of specialty treatment centers, improved diagnostic accuracy for hae, growing patient advocacy initiatives.

The hereditary angioedema market size is expected to see strong growth in the next few years. It will grow to $4.15 billion in 2030 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to expansion of novel oral and subcutaneous therapies, increasing investment in rare disease drug development, rising adoption of personalized medicine approaches, growth in genetic screening programs, improved long-term disease management strategies. Major trends in the forecast period include increasing adoption of targeted bradykinin therapies, rising use of prophylactic treatment regimens, growing focus on early genetic diagnosis, expansion of home-based self-administration therapies, enhanced patient-centric treatment approaches.

The increasing prevalence of rare diseases is expected to drive the growth of the hereditary angioedema market in the coming years. Rare diseases, often referred to as orphan diseases, are medical conditions that affect a relatively small proportion of the population. The rising occurrence of these diseases can be attributed to factors such as advancements in medical research, shifts in population demographics, and environmental influences. Hereditary angioedema (HAE) represents a notable rare disease, underscoring the need for specialized treatments and greater awareness due to its potentially life-threatening swelling episodes. Its genetic origin and low prevalence make early diagnosis and targeted therapeutic approaches critical for effective disease management and improved patient outcomes. For example, in January 2025, according to the American Cancer Society, a US-based professional organization, an estimated 59,660 new cases of oral cavity and oropharyngeal cancer are expected to be diagnosed in 2025, with approximately 12,770 deaths projected from these conditions. As a result, the rising prevalence of rare diseases is contributing to the expansion of the hereditary angioedema market.

Key players operating in the hereditary angioedema market are developing innovative therapies, including oral plasma kallikrein inhibitors, to offer more convenient and effective on-demand treatment options for patients. Oral plasma kallikrein inhibitors are medications designed to block plasma kallikrein activity, thereby preventing excessive production of bradykinin, and are primarily used in the treatment of hereditary angioedema. For instance, in September 2024, KalVista Pharmaceuticals, Inc., a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration had accepted its new drug application for sebetralstat. This investigational oral plasma kallikrein inhibitor is intended for the on-demand treatment of hereditary angioedema attacks in adult and pediatric patients aged 12 years and older. Sebetralstat introduces a novel therapeutic approach by directly targeting and inhibiting plasma kallikrein, and the acceptance of the NDA marks a significant step toward potential regulatory approval and commercialization.

In July 2023, BioCryst Pharmaceuticals, Inc., a US-based biopharmaceutical company, entered into a partnership with Er-Kim Pharmaceuticals to commercialize ORLADEYO in Turkey. Through this collaboration, BioCryst aims to expand patient access to ORLADEYO (berotralstat) for individuals with hereditary angioedema in Turkey while reinforcing its footprint in the global rare disease market. Er-Kim Pharmaceuticals is a Turkey-based company engaged in the development, manufacturing, and marketing of high-quality pharmaceutical products across multiple therapeutic areas.

Major companies operating in the hereditary angioedema market are Takeda Pharmaceutical Company Limited, CSL Limited, Sanofi S.A., Pharming Group N.V., BioCryst Pharmaceuticals Inc., KalVista Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Intellia Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Astria Therapeutics Inc., Pharvaris N.V., Adverum Biotechnologies Inc., ADARx Pharmaceuticals Inc., Attune Pharmaceuticals Inc., Lev Pharmaceuticals Inc., BioMarin Pharmaceutical Inc., Spark Therapeutics Inc., Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Regeneron Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, Alnylam Pharmaceuticals Inc.

North America was the largest region in the hereditary angioedema market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hereditary angioedema market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the hereditary angioedema market by increasing costs of imported plasma-derived products, biologic manufacturing inputs, drug formulation materials, and specialized cold-chain logistics services. North America and Europe are most affected due to reliance on cross-border sourcing of biologics and active pharmaceutical ingredients, while Asia-Pacific faces higher costs for advanced therapeutic imports. These tariffs are raising treatment costs and affecting pricing strategies for rare disease therapies. However, they are also encouraging localized biologics manufacturing, regional supply chain diversification, and long-term investments in domestic rare disease treatment production.

The hereditary angioedema market research report is one of a series of new reports that provides hereditary angioedema market statistics, including hereditary angioedema industry global market size, regional shares, competitors with a hereditary angioedema market share, detailed hereditary angioedema market segments, market trends and opportunities, and any further data you may need to thrive in the hereditary angioedema industry. This hereditary angioedema market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hereditary angioedema (HAE) is a rare inherited disorder marked by recurring episodes of severe swelling affecting the skin, gastrointestinal tract, and airways, resulting from a deficiency or dysfunction of the C1 esterase inhibitor. It arises from genetic mutations that disrupt the complement system, leading to excessive production of bradykinin. HAE can become life threatening when swelling involves the airways, necessitating timely treatment with C1 inhibitor replacement therapies or bradykinin-targeted treatments.

The primary forms of hereditary angioedema include type I and type II. Type I hereditary angioedema is the most prevalent form and is caused by reduced levels of C1 esterase inhibitor (C1-INH), which results in uncontrolled bradykinin generation and repeated swelling episodes. Management of HAE is generally categorized into prophylactic and on-demand therapies, involving drug classes such as C1 esterase inhibitors, bradykinin receptor antagonists, kallikrein inhibitors, and other therapeutic classes. These treatments are delivered through multiple routes, including subcutaneous, intravenous, and oral administration, and are distributed via hospital pharmacies, retail pharmacies, and online pharmacies.

The hereditary angioedema market consists of revenues earned by entities by providing services such as diagnosis and genetic testing, acute attack management, and long-term prevention. The market value includes the value of related goods sold by the service provider or included within the service offering. The hereditary angioedema market also includes sales of plasma-derived products, biologics, and therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.